Trial Outcomes & Findings for Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. (NCT NCT03552276)
NCT ID: NCT03552276
Last Updated: 2024-11-21
Results Overview
Please refer to Adverse event section for more information
Recruitment status
COMPLETED
Study phase
PHASE2/PHASE3
Target enrollment
281 participants
Primary outcome timeframe
upto week 208
Results posted on
2024-11-21
Participant Flow
This was a long-term extension (LTE) study in subjects with Psoriatic arthritis who had completed the treatment with tildra in the parent study,CLR\_16\_23(NCT02980692). In LTE, there was no randomization and subjects continued to receive the treatment assigned during the parent study into the LTE upto Wk 52 to maintain blind of the parent study. Post the DBL of CLR 16-23, the blind was no longer needed, all subjects who had entered the LTE study received open label dose of tildra 100 mg q12 wks.
Participant milestones
| Measure |
Tildrakizumab 200 mg q4 Weeks
The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 200 mg q12 Weeks
The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 100 mg q12 Weeks
These subjects continued to receive same dose of tildrakizumab 100 mg q12 weeks in the LTE study as in the parent study. However, in the LTE study, post DBL of the parent study, the dose was open label
|
Tildrakizumab 200 mg q4 Weeks Switched to Tildrakizumab 100 mg q12 Weeks
This group represents subjects who switched from tildrakizumab 200 mg q4 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study.
|
Tildrakizumab 200 mg q12 Weeks Switched to Tildrakizumab 100 mg q12 Weeks
This group represents subjects who switched from tildrakizumab 200 mg q12 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study
|
|---|---|---|---|---|---|
|
Overall Study
STARTED
|
5
|
22
|
49
|
54
|
151
|
|
Overall Study
COMPLETED
|
0
|
0
|
33
|
46
|
126
|
|
Overall Study
NOT COMPLETED
|
5
|
22
|
16
|
8
|
25
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Baseline characteristics by cohort
| Measure |
Tildrakizumab q4 Weeks, 200 mg
n=5 Participants
The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 200 mg q12 Weeks
n=22 Participants
The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 100 mg q12 Weeks
n=49 Participants
These subjects continued to receive same dose of tildrakizumab 100 mg q12 weeks in the LTE study as in the parent study. However, in the LTE study, post DBL of the parent study, the dose was open label.
|
Tildrakizumab 200 mg q4 Weeks Switched to Tildrakizumab 100 mg q12 Weeks
n=54 Participants
This group represents subjects who switched from tildrakizumab 200 mg q4 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study.
|
Tildrakizumab 200 mg q12 Weeks Switched to Tildrakizumab 100 mg q12 Weeks
n=151 Participants
This group represents subjects who switched from tildrakizumab 200 mg q12 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study
|
Total
n=281 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|
|
Age, Continuous
|
65.0 years
STANDARD_DEVIATION 11.96 • n=5 Participants
|
53.8 years
STANDARD_DEVIATION 14.80 • n=7 Participants
|
50.6 years
STANDARD_DEVIATION 11.35 • n=5 Participants
|
49.9 years
STANDARD_DEVIATION 13.47 • n=4 Participants
|
48.3 years
STANDARD_DEVIATION 11.93 • n=21 Participants
|
49.7 years
STANDARD_DEVIATION 12.57 • n=8 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
13 Participants
n=7 Participants
|
28 Participants
n=5 Participants
|
33 Participants
n=4 Participants
|
77 Participants
n=21 Participants
|
152 Participants
n=8 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=5 Participants
|
9 Participants
n=7 Participants
|
21 Participants
n=5 Participants
|
21 Participants
n=4 Participants
|
74 Participants
n=21 Participants
|
129 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
22 Participants
n=21 Participants
|
39 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
3 Participants
n=5 Participants
|
19 Participants
n=7 Participants
|
43 Participants
n=5 Participants
|
48 Participants
n=4 Participants
|
129 Participants
n=21 Participants
|
242 Participants
n=8 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
|
Race (NIH/OMB)
White
|
5 Participants
n=5 Participants
|
21 Participants
n=7 Participants
|
48 Participants
n=5 Participants
|
53 Participants
n=4 Participants
|
147 Participants
n=21 Participants
|
274 Participants
n=8 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
PRIMARY outcome
Timeframe: upto week 208Please refer to Adverse event section for more information
Outcome measures
| Measure |
Tildrakizumab 200 mg q4 Weeks
n=5 Participants
The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 200 mg q12 Weeks
n=22 Participants
The subjects in this group entered the LTE study from the parent study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 100 mg q12 Weeks
n=49 Participants
These subjects continued to receive same dose of tildrakizumab 100 mg q12 weeks in the LTE study as in the parent study. However, in the LTE study, post DBL of the parent study, the dose was open label.
|
Tildrakizumab 200 mg q4 Weeks Switched to Tildrakizumab 100 mg q12 Weeks
n=54 Participants
This group represents subjects who switched from tildrakizumab 200 mg q4 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study.
|
Tildrakizumab 200 mg q12 Weeks Switched to Tildrakizumab 100 mg q12 Weeks
n=151 Participants
This group represents subjects who switched from tildrakizumab 200 mg q12 weeks dose to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study
|
|---|---|---|---|---|---|
|
Number of Participants With Adverse Events
|
5 Participants
|
14 Participants
|
36 Participants
|
44 Participants
|
125 Participants
|
Adverse Events
Tildrakizumab 200 mg, q4 Weeks
Serious events: 3 serious events
Other events: 5 other events
Deaths: 0 deaths
Tildrakizumab 200 mg, q12 Weeks
Serious events: 2 serious events
Other events: 14 other events
Deaths: 1 deaths
Tildrakizumab 100 mg q12 Weeks
Serious events: 7 serious events
Other events: 36 other events
Deaths: 0 deaths
Tildrakizumab 200 mg q4 Weeks, to Tildrakizumab 100 mg q12 Weeks
Serious events: 3 serious events
Other events: 44 other events
Deaths: 0 deaths
Tildrakizumab 200 mg q12 Weeks, to Tildrakizumab 100 mg q12 Weeks
Serious events: 25 serious events
Other events: 125 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
Tildrakizumab 200 mg, q4 Weeks
n=5 participants at risk
The subjects in this group entered the LTE, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 200 mg, q12 Weeks
n=22 participants at risk
The subjects in this group entered the LTE study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 100 mg q12 Weeks
n=49 participants at risk
These subjects continued to receive same dose of tildrakizumab 100 mg q12 weeks in the LTE study as in the parent study. However, in the LTE, post DBL of the parent study, the dose was open label.
|
Tildrakizumab 200 mg q4 Weeks, to Tildrakizumab 100 mg q12 Weeks
n=54 participants at risk
This group represents subjects who switched from tildrakizumab 200 mg q4 weeks to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study.
|
Tildrakizumab 200 mg q12 Weeks, to Tildrakizumab 100 mg q12 Weeks
n=151 participants at risk
This group represents subjects who switched from tildrakizumab 200 mg q4 weeks to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study
|
|---|---|---|---|---|---|
|
Infections and infestations
Gallbladder empyema
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Intestinal sepsis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Haemorrhagic erosive gastritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Generalised oedema
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Abdominal abscess
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Septic shock
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Craniocerebral injury
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Biopsy kidney
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma metastatic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Retinal migraine
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Tension headache
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Calculus urinary
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
End stage renal disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Hydrocele female
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Surgical and medical procedures
Gastric bypass
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Aortic dissection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Arteriosclerosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Hypertension
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Hypertensive crisis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
Other adverse events
| Measure |
Tildrakizumab 200 mg, q4 Weeks
n=5 participants at risk
The subjects in this group entered the LTE, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 200 mg, q12 Weeks
n=22 participants at risk
The subjects in this group entered the LTE study, however, they discontinued from the study and were not switched to the open label tildrakizumab 100 mg q12 weeks dose.
|
Tildrakizumab 100 mg q12 Weeks
n=49 participants at risk
These subjects continued to receive same dose of tildrakizumab 100 mg q12 weeks in the LTE study as in the parent study. However, in the LTE, post DBL of the parent study, the dose was open label.
|
Tildrakizumab 200 mg q4 Weeks, to Tildrakizumab 100 mg q12 Weeks
n=54 participants at risk
This group represents subjects who switched from tildrakizumab 200 mg q4 weeks to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study.
|
Tildrakizumab 200 mg q12 Weeks, to Tildrakizumab 100 mg q12 Weeks
n=151 participants at risk
This group represents subjects who switched from tildrakizumab 200 mg q4 weeks to open label tildrakizumab 100 mg q12 weeks dose in the LTE study, post DBL of the parent study
|
|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Blood and lymphatic system disorders
Neutrophilia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Diastolic dysfunction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Pericardial cyst
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Cardiac disorders
Tricuspid valve incompetence
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Congenital, familial and genetic disorders
Accessory spleen
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Congenital, familial and genetic disorders
Gilbert's syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Congenital, familial and genetic disorders
Hydrocele
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Endocrine disorders
Goitre
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Endocrine disorders
Hypothyroidic goitre
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Endocrine disorders
Thyroid mass
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Astigmatism
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Blepharitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Blindness transient
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Cataract
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Cataract nuclear
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Diabetic retinopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Keratitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Myopia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Retinal vascular disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Eye disorders
Visual acuity reduced
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
8.2%
4/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Abdominal rigidity
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Anal fistula
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Aphthous ulcer
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Barrett's oesophagus
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Coeliac artery stenosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Dental caries
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.1%
3/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Diaphragmatic hernia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
18.2%
4/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.1%
3/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
7.4%
4/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.0%
6/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Diverticulum
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Duodenitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Gastritis erosive
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Gingival swelling
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Haemorrhagic erosive gastritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Intestinal metaplasia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Nausea
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.0%
6/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Pancreatitis chronic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Rectal polyp
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Retained deciduous tooth
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Asthenia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Chest pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Chills
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Drug intolerance
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Fatigue
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Generalised oedema
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Influenza like illness
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Injection site erythema
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Injection site pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Injection site pruritus
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Injection site rash
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Injection site reaction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Injury associated with device
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Oedema peripheral
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Pyrexia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.1%
3/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
7.4%
4/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Vaccination site pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
General disorders
Xerosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Biliary dyskinesia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Diabetic hepatopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Gallbladder polyp
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Hepatic steatosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Hepatitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Non-alcoholic steatohepatitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Hepatobiliary disorders
Steatohepatitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Immune system disorders
Allergy to arthropod bite
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Immune system disorders
Allergy to plants
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Abdominal abscess
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Acute sinusitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Adenovirus infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Bacteriuria
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Bartholin's abscess
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Breast abscess
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
COVID-19
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.1%
3/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
20.4%
11/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
16.6%
25/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Chronic sinusitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Coronavirus infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Cystitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Erythema migrans
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Escherichia infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Furuncle
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Gallbladder empyema
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Gastrointestinal bacterial overgrowth
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Gastrointestinal infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Gingivitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Helicobacter gastritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Herpes simplex
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Hordeolum
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Influenza
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Intestinal sepsis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Joint abscess
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Laryngitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Localised infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
14.3%
7/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
14.8%
8/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
13.9%
21/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Otitis externa
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Otitis media
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Periodontitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.0%
9/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pharyngotonsillitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pneumonia bacterial
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pulmonary tuberculosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pulpitis dental
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Purulent discharge
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Pyelonephritis acute
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Respiratory tract infection viral
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.1%
3/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
8.6%
13/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Septic shock
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Skin infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Suspected COVID-19
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Tonsillitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Tracheitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Tracheobronchitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
14.3%
7/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
16.7%
9/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
8.6%
13/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Urinary tract infection
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
5.6%
3/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
11.9%
18/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Viral infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Viral pharyngitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Vulvovaginal mycotic infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Infections and infestations
Wound infection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Burns second degree
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Craniocerebral injury
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Cuboid syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Epicondylitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Iliotibial band syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Immunisation reaction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Nail avulsion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Post vaccination syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Synovial rupture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Tendon injury
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Alanine aminotransferase increased
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Apolipoprotein B increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Aspartate aminotransferase increased
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Bilirubin conjugated increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Bilirubin urine present
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Biopsy kidney
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood glucose increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood pressure increased
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.1%
3/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood triglycerides increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Blood urea increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
C-reactive protein increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.3%
5/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Glomerular filtration rate decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Haematocrit decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Hepatic enzyme increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Low density lipoprotein increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Monocyte count decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Platelet count decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Prostatic specific antigen increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Red blood cell count decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Transaminases increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Urinary casts
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Weight decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
Weight increased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
5.6%
3/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.6%
7/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Cholesterosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Copper deficiency
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Dyslipidaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.0%
6/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Impaired fasting glucose
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Insulin resistance
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
5.6%
3/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.0%
6/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
13.6%
3/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.0%
6/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
8.2%
4/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.0%
6/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Dactylitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Exostosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Fracture pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Greater trochanteric pain syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc displacement
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Jaw cyst
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Joint contracture
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Metatarsalgia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Osteochondrosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Periarticular disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Pseudarthrosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Psoriatic arthropathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.0%
9/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Sacroiliitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Spinal disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.7%
2/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis stenosans
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Musculoskeletal and connective tissue disorders
Trigger finger
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma metastatic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal adenoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anogenital warts
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign oesophageal neoplasm
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of liver
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic adenoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Anosmia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Bradykinesia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Cervicobrachial syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Diabetic neuropathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Headache
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.1%
3/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
7.4%
4/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
8.6%
13/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Lumbosacral radiculopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Migraine
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Myotonia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Neuritis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Parkinson's disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Retinal migraine
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.6%
4/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Sensory loss
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Spinal cord haematoma
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
20.0%
1/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Syncope
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Nervous system disorders
Tension headache
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Adjustment disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Affective disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Depression
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Irritability
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Mixed anxiety and depressive disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Sleep disorder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Psychiatric disorders
Stress
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Calculus urinary
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Cystitis haemorrhagic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Cystitis noninfective
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
End stage renal disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Glomerulonephritis chronic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Hypertonic bladder
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Nephrosclerosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
3/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Renal cyst
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Stress urinary incontinence
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Renal and urinary disorders
Urinary tract inflammation
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Abnormal uterine bleeding
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Adenomyosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Bartholin's cyst
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Hydrocele female
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Intermenstrual bleeding
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Menstruation irregular
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Reproductive system and breast disorders
Vaginal discharge
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Surgical and medical procedures
Gastric bypass
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract inflammation
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Dermatitis psoriasiform
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Hidradenitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
3.3%
5/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.1%
2/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Aortic arteriosclerosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Aortic dissection
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.5%
1/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Arteriosclerosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Bleeding varicose vein
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Blood pressure fluctuation
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Diabetic microangiopathy
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Essential hypertension
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Hypertension
|
40.0%
2/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
4.1%
2/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
9.3%
5/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
6.6%
10/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Hypertensive crisis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
2.0%
1/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Lymphostasis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Peripheral venous disease
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.9%
1/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
1.3%
2/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Phlebitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
|
Vascular disorders
Thrombophlebitis
|
0.00%
0/5 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/22 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/49 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.00%
0/54 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
0.66%
1/151 • Week 208
The subjects rolled over to the LTE study from the parent study (CLR-16-23) continued to receive the dose as per the parent study upto Week 52 to ensure that blinding of the parent study is maintained. Thereafter, once the data base lock (DBL) of the parent study occurred and the blinding was no longer needed subjects received open label tildrakizumab 100 mg q12 weeks.
|
Additional Information
Head-Regulatory Affairs
Sun Pharmaceutical Industries Limited
Phone: 2266455645
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place